Drug search by name

Tisagenlecleucel Intravenous and Inflammatory disorders

Result of checking the interaction of drug Tisagenlecleucel Intravenous and disease Inflammatory disorders for safety when used together.

Check result:

Tisagenlecleucel Intravenous <> Inflammatory disorders

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Drugs directed against B cells, such as axicabtagene ciloleucel, and tisagenlecleuce should not be administered to patients with inflammatory disorders. Cytokine Release Syndrome, including fatal or life-threatening reactions, occurred in patients receiving these agents. Axicabtagene ciloleucel and tisagenlecleuce are CD19-directed genetically modified autologous T cell immunotherapy that bind to CD19-expressing cancer cells and normal B cells and through a series of cascades, lead T cell activation and secretions of inflammatory cytokines.

Tisagenlecleucel Intravenous

Generic Name: tisagenlecleucel

Brand Name: Kymriah

Synonyms: Tisagenlecleucel

What is Tisagenlecleucel Intravenous?